Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro - PubMed (original) (raw)
. 2002 Jan 1;99(1):319-25.
doi: 10.1182/blood.v99.1.319.
Affiliations
- PMID: 11756187
- DOI: 10.1182/blood.v99.1.319
Free article
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
Susan M Graham et al. Blood. 2002.
Free article
Abstract
In clinical trials, the tyrosine kinase inhibitor STI571 has proven highly effective in reducing leukemic cell burden in chronic myeloid leukemia (CML). The overall sensitivity of CML CD34(+) progenitor cells to STI571 and the degree to which cell death was dependent on cell cycle status were determined. Stem cells (Lin(-)CD34(+)) from the peripheral blood of patients with CML in chronic phase and from granulocyte-colony-stimulating factor-mobilized healthy donors were labeled with carboxy-fluorescein diacetate succinimidyl diester dye to enable high-resolution tracking of cell division. Then they were cultured for 3 days with and without growth factors +/- STI571. After culture, the cells were separated by fluorescence-activated cell sorting into populations of viable quiescent versus cycling cells for genotyping. For healthy controls, in the presence of growth factors, STI571 affected neither cell cycle kinetics nor recovery of viable cells. In the absence of growth factors, normal cells were unable to divide. For CML samples, in the presence or absence of growth factors, the response to STI571 was variable. In the most sensitive cases, STI571 killed almost all dividing cells; however, a significant population of viable CD34(+) cells was recovered in the undivided peak and confirmed to be part of the leukemic clone. STI571 also appeared to exhibit antiproliferative activity on the quiescent population. These studies confirm that CML stem cells remain viable in a quiescent state even in the presence of growth factors and STI571. Despite dramatic short-term responses in vivo, such in vitro insensitivity to STI571, in combination with its demonstrated antiproliferative activity, could translate into disease relapse after prolonged therapy.
Similar articles
- [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
Song YP, Fang BJ, Wei XD, Zheng S. Song YP, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Dec;13(6):1004-9. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005. PMID: 16403268 Chinese. - Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ. Bhatia R, et al. Blood. 2003 Jun 15;101(12):4701-7. doi: 10.1182/blood-2002-09-2780. Epub 2003 Feb 6. Blood. 2003. PMID: 12576334 - Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Holtz MS, et al. Blood. 2002 May 15;99(10):3792-800. doi: 10.1182/blood.v99.10.3792. Blood. 2002. PMID: 11986238 - [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M, Toga W. Nakajima M, et al. Nihon Yakurigaku Zasshi. 2003 Dec;122(6):482-90. doi: 10.1254/fpj.122.482. Nihon Yakurigaku Zasshi. 2003. PMID: 14639002 Review. Japanese. - STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
O'Dwyer ME, Druker BJ. O'Dwyer ME, et al. Lancet Oncol. 2000 Dec;1:207-11. doi: 10.1016/s1470-2045(00)00149-2. Lancet Oncol. 2000. PMID: 11905636 Review.
Cited by
- CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells.
Sinclair A, Park L, Shah M, Drotar M, Calaminus S, Hopcroft LE, Kinstrie R, Guitart AV, Dunn K, Abraham SA, Sansom O, Michie AM, Machesky L, Kranc KR, Graham GJ, Pellicano F, Holyoake TL. Sinclair A, et al. Blood. 2016 Jul 21;128(3):371-83. doi: 10.1182/blood-2015-08-661785. Epub 2016 May 24. Blood. 2016. PMID: 27222476 Free PMC article. - Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model.
Imeri J, Marcoux P, Huyghe M, Desterke C, Fantacini DMC, Griscelli F, Covas DT, de Souza LEB, Griscelli AB, Turhan AG. Imeri J, et al. Front Immunol. 2024 Jan 8;14:1309010. doi: 10.3389/fimmu.2023.1309010. eCollection 2023. Front Immunol. 2024. PMID: 38259442 Free PMC article. - Leukemia stem cells: the root of chronic myeloid leukemia.
Zhou H, Xu R. Zhou H, et al. Protein Cell. 2015 Jun;6(6):403-12. doi: 10.1007/s13238-015-0143-7. Epub 2015 Mar 10. Protein Cell. 2015. PMID: 25749979 Free PMC article. Review. - Mechanisms determining the fate of hematopoietic stem cells.
Lin S, Zhao R, Xiao Y, Li P. Lin S, et al. Stem Cell Investig. 2015 May 15;2:10. doi: 10.3978/j.issn.2306-9759.2015.05.01. eCollection 2015. Stem Cell Investig. 2015. PMID: 27358878 Free PMC article. Review. - Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Müller-Tidow C, Bhatia R, Brunton VG, Koschmieder S, Holyoake TL. Hamilton A, et al. Blood. 2012 Feb 9;119(6):1501-10. doi: 10.1182/blood-2010-12-326843. Epub 2011 Dec 19. Blood. 2012. PMID: 22184410 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical